GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q32 Bio Inc (NAS:QTTB) » Definitions » ROC (Joel Greenblatt) %

Q32 Bio (Q32 Bio) ROC (Joel Greenblatt) % : -746.72% (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Q32 Bio ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Q32 Bio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -746.72%.

The historical rank and industry rank for Q32 Bio's ROC (Joel Greenblatt) % or its related term are showing as below:

QTTB' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -18075.37   Med: -837.34   Max: -502.99
Current: -502.99

During the past 3 years, Q32 Bio's highest ROC (Joel Greenblatt) % was -502.99%. The lowest was -18075.37%. And the median was -837.34%.

QTTB's ROC (Joel Greenblatt) % is ranked worse than
57.25% of 1462 companies
in the Biotechnology industry
Industry Median: -319.81 vs QTTB: -502.99

Q32 Bio's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Q32 Bio ROC (Joel Greenblatt) % Historical Data

The historical data trend for Q32 Bio's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Q32 Bio ROC (Joel Greenblatt) % Chart

Q32 Bio Annual Data
Trend Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
-18,075.37 -837.34 -559.51

Q32 Bio Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial -345.23 -321.75 - -1,256.91 -746.72

Competitive Comparison of Q32 Bio's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Q32 Bio's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Q32 Bio's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Q32 Bio's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Q32 Bio's ROC (Joel Greenblatt) % falls into.



Q32 Bio ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 2.344) - (9.69 + 0 + 3.003)
=-10.349

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 2.168) - (18.819 + 0 + 9.486)
=-26.137

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Q32 Bio for the quarter that ended in Mar. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-59.372/( ( (8.083 + max(-10.349, 0)) + (7.819 + max(-26.137, 0)) )/ 2 )
=-59.372/( ( 8.083 + 7.819 )/ 2 )
=-59.372/7.951
=-746.72 %

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Q32 Bio  (NAS:QTTB) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Q32 Bio ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Q32 Bio's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Q32 Bio (Q32 Bio) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
830 Winter Street, Waltham, MA, USA, 02451
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

Q32 Bio (Q32 Bio) Headlines

From GuruFocus